BCCA Protocol Summary for Palliative Therapy for Advanced Breast Cancer Using Letrozole (FEMARA®)

**Protocol Code**  
BRAVLET

**Tumour Group**  
Breast

**Contact Physician**  
Dr. Susan Ellard

**ELIGIBILITY:**
- First or second line hormonal treatment for advanced breast cancer in postmenopausal women.

**EXCLUSION CRITERIA:**
- Premenopausal women.
- Patients who have progressed on an alternate aromatase inhibitor (note: may be used by patients who cannot tolerate an alternate aromatase inhibitor).

**TESTS:**  
None required.

**TREATMENT:**
Letrozole 2.5 mg po daily until evidence of progression.

**PRECAUTIONS:**
1. **Hepatic dysfunction:** Letrozole is considered safe in mild-to-moderate hepatic dysfunction but has not been studied in severe hepatic dysfunction.

Contact Dr. Susan Ellard or tumour group delegate at (250) 712-3900 or 1-888-563-7773 with any problems or questions regarding this treatment program.

**Date Activated:** 01 Sept 1998  
**Date Revised:** 01 May 2009 (unsafe abbreviations and symbols replaced, physician contact revised)

**References**